euclises pharmaceuticals inc private company information  bloomberg july    pm et pharmaceuticals company overview of euclises pharmaceuticals inc snapshot people company overview euclises pharmaceuticals inc researches develops and commercializes medicines in the field of inflammation and oncology euclises pharmaceuticals inc was formerly known as talley newco inc the company was incorporated in  and is based in saint louis missouri  forest park avenuesuite saint louis mo united statesfounded in  phone  wwweuclisescom key executives for euclises pharmaceuticals inc dr bobby w sandage jr phd chief executive officer president and director age  compensation as of fiscal year  euclises pharmaceuticals inc key developments euclises pharmaceuticals inc presents at th annual conference biotech showcase jan  am nov   euclises pharmaceuticals inc presents at th annual conference biotech showcase jan  am venue hilton san francisco union square  ofarrell street san francisco ca  united states speakers bobby w sandage chief executive officer president and director euclises pharmaceuticals inc presents at redefining early stage investments resi conference  jan jan   euclises pharmaceuticals inc presents at redefining early stage investments resi conference  jan  venue marines memorial club  hotel  sutter st san francisco ca  united states euclises pharmaceuticals inc receives patent from european patent office for new class of compounds for treatment of cancer pain and inflammation dec   euclises pharmaceuticals inc has received a notice of allowance from the european patent office for patent application no  entitled deuterated benzopyran compounds and application thereof the covered compounds have been shown to be very potent and highly selective in the inhibition the cox enzyme the patent broadly covers some of the company’s novel compounds including its lead drug ecp which has demonstrated significant slowing of tumor growth in animal models of cancer euclises is currently focused n completing the indenabling studies in anticipation of initiating clinical trials late in  in patients with colorectal cancer cox has been shown to play a critical role in tumorigenesis progression and development of resistance to standardofcare chemotherapies in a number of cancers including nsclc crc pancreatic cancer renal cell cancer cutaneous squamous cell carcinoma and basal cell carcinoma while the role of cox in cancer has been well known for some time older cox inhibitors have not been effectively developed for oncology treatment in part due to side effects that limit dosing use of these older inhibitors in initial clinical studies has however firmly validated the efficacy of cox inhibition in cancer and also facilitated the identification of a noninvasive biomarker that allows selection and monitoring of patients whose tumors are dependent on the cox pathway euclises new classes of cox inhibitors appear to possess the favorable characteristics of the older drugs but are expected to support clinically optimal anticancer dose levels safely similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact euclises pharmaceuticals inc please visit wwweuclisescom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close euclises pharmaceuticals announces series a financing employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       euclises pharmaceuticals announces series a financing tweet   am st louisbusiness wireeuclises pharmaceuticals inc a biotechnology company developing novel cox inhibitors for the treatment of cancer today announced closing a  million series a financing founded by john talley one of the pioneers of selective cyclooxygenase “cox” inhibitors euclises will use proceeds from the financing to prepare its euclicoxib® product candidates for clinical trials in cancer patients euclises’ series a financing was led by cultivation capital a st louisbased earlystage venture capital firm and included participation by biogenerator missouri technology corporation abc laboratories the st louis county port authority’s helix fund and the st louis arch angels help employers find you check out all the jobs and post your resume read at biospacecom related news fresh from cofounding massively financed juno therapeutics arch venture partners banks  million to back new biotechs poxel nails  million from new investors vc firm targeted technology secures  million geared towards earlystage biotechs nanoviricides inc nnvcpk raises approximately  million upon exercise of certain old warrants by its long standing investors edge therapeutics grabs  million venture loan vaccinogen plans move to baltimore after  million in new funding will increase headcount by  percent feds to provide as much as  million to tiny san diegobased mapp biopharmaceutical menlo park startup armetheon snags  million series a financing sgb makes breakthrough with new hybrid jatropha closes m series c financing massachusetts civitas therapeutics locks in  million please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • euclises pharmaceuticals   • biotechpharma  finance • biotechpharma  finance startup                 microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one bobby sandage euclises pharmaceuticals inc profile  biography  bloomberg feedback bobby sandage presidentceo euclises pharmaceuticals inc career history general partner cultivation capital present presidentceo euclises pharmaceuticals inc present president coronado biosciences inc  presidentceo coronado biosciences inc  vpheadoncology rd covidiens pharmaceuticals  exec vpresearch  development indevus pharmaceuticals inc  exec vpresearch  development interneuron pharmaceuticals  senior vpresearch  devpt interneuron pharmaceuticals  vpresearch  development interneuron pharmaceuticals  executive vice president endo pharmaceuticals hldgs inc former vpembedded therapeutics covidien plc former dupont pharmaceuticals co former show more website wwweuclisescom corporate information address  forest park avenue suite  saint louis mo  united states phone  fax  web url wwweuclisescom from the web personal information education purdue university phd university of arkansas at little rock bachelors degree pharmacy memberships board memberships immunophotonics inc board member present mateon therapeutics inc board member present euclises pharmaceuticals inc board member present gentium spa board member  coronado biosciences inc board member  osteologix inc board member unknown genta inc board member  show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data euclises pharmaceuticals inc  st louis mo usa startup start up confidently with gust launch all the legal accounting and financial tools you need to start and run your company overview executive summary financials documents euclises pharmaceuticals inc euclises exploits the well validated cancer target cox with novel inhibitors that dramatically improve safety  anticancer efficacy stage product in development industry biotechnology location st louis mo usa currency usd founded october  employees  company summary euclises  founded by celebrex inventor john talley  is focused on novel cox inhibitors with improved safety  efficacy allowing effective treatment of many cancers such as lung colorectal  pancreatic cox in cancer has been appreciated but older drugs such as celebrex have not been effectively developed for this clinical studies with these however have validated both the impact of cox in cancer  biomarkers for patient selection team randall weiss cofounder rajesh devraj president  ceo over  years experience in drug discovery and development business development and strategy previously sr vice president deciphera pharmaceuticals prior to that served as svp head of scientific  portfolio strategy at jubilant biosys and sr dir and res fellow in med chem and discovery res with pfizer rd has led teams that have advanced eight candidates to clinical trials he currently serves on sab of deciphera pharmaceuticals robert alan beardsley executive chair two decades experience leading oncology drug startups also exec chair of galera therapeutics a clinicalstage company backed by novartis ventures  nea previously ceo of galera msdc kereos  metaphore pharmaceuticals key leader in advancing seven candidates through clinical trials served serves on boards of multiple biotech pharmaceutical companies ranging from preseed to public and has raised m in venture capital support john talley cso one of the world’s most accomplished med chemists  inventor of celebrex® as well as several other marketed medicines with over  years of drugmaking experience he is also cofounder of sarmont a key chemistry collaborator for the company previously served as svp at ironwood pharmaceuticals  in various roles at g d searle his track record in bringing drugs to market is unrivalled with more than  issued us patents eduardo martinez vp of drug discovery significant experience starting small chemistrydriven companies  directing drug discovery he is also a cofounder of sarmont a key chemistry collaborator for the company previously was at medros where he led the company drug discovery operations and at ironwood pharmaceuticals where he started the chemistry group and led a team of chemists to advance two candidates into the clinic robert calcaterra cofounder robert karr cofounder robert beardsley advisors andrew hoyne  polsinelli corporate timothy keane  harness dickey pierce corporate lawyer unconfirmed judy ballard  right on site bookkeeping stone carlie tax accountant unconfirmed previous investors arch angels eulises angels llc unconfirmed biogenerator unconfirmed loading gust  gust start up confidently with gust launch all the legal accounting and financial tools you need to start and run your company overview executive summary financials documents euclises pharmaceuticals inc euclises exploits the well validated cancer target cox with novel inhibitors that dramatically improve safety  anticancer efficacy stage product in development industry biotechnology location st louis mo usa currency usd founded october  employees  only investors on gust who have been granted access can view this content interested in this startup sign in or sign up to request more information loading right dose  euclises          right dose clinical studies with coxibs have shown that anticancer efficacy continues to increase as coxib doses rise above the approved and clinically accepted doses used for rheumatoid arthritis osteoarthritis or acute pain these coxib doses approved for pain and inflammation are unable to achieve complete pharmacological suppression of the high levels of cox activity in tumor cells and the tumorimmune microenvironment as is necessary to afford good anticancer efficacy euclicoxibs™ allow for safe use of the higher doses required for maximal cox inhibition biomarker suppression and anticancer efficacy         board of directors  euclises board of directors   rick ryan phd mba – chair cultivation capital   charlie bolten biogenerator   robert calcaterra dsc exeteur group   rajesh devraj phd atlas ventures   bobby w sandage jr phd – president  ceo   john talley phd – cso   robert beardsley phd mba   right drug  euclises          right drug coxibs were developed and approved for the chronic treatment of pain and inflammation  use of high doses of coxibs to effectively treat cancer has been limited due to potential safety issues in combination with standardofcare soc chemotherapeutics and targeted therapy  euclicoxibs™ are designed to both increase anticancer potency and safely reach higher dosesexposures required for maximal anticancer effectiveness while mitigating sideeffects with combination therapies  euclicoxibs™ are expected to be the right drugs to use in combination with soc to treat refractory cancers that are driven by cox and are sensitive to cox inhibition         about us  euclises about us euclises pharmaceuticals inc is a drug discovery and development company advancing the next generation of oral smallmolecule drugs that target cox to disrupt the tumor microenvironment and kill cancer cells blocking this key target has been shown to a slow tumor growth b augment the activity of immune checkpoint inhibitors by eliminating coxpge mediated tumor immune evasion and c boost the efficacy of other targeted agents such as egfr inhibitors by shutting down resistance pathways our mission is to advance these new molecules in combinations with both immune checkpoint and egfr inhibitors through initial clinical trials we believe this approach has the potential to dramatically improve the overall efficacy of current immunooncology therapies and egfr inhibitors and to expand the number of patients who benefit from these agents euclises boasts a team of pharmaceutical veterans who have led development of dozens of clinical candidates and marketed drugs euclises layerslider targeting clinicallyproven cancer biology expanding who will respond to immunooncology therapies combining with other targeted therapies to go beyond stopping progression and save lives selecting patients who will respond harnessing potent  selective candidates to achieve new levels of efficacy leveraging an experienced drug development team below slider euclises’ next generation therapies prevent tumor immune evasion and kill cancer by disrupting the tumor microenvironment right patient cancers driven by cox read more  right drug euclicoxibs® designed to safely treat cancers read more  right dose maximize anticancer efficacy read more